Sharemaestro Newsreel

Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum

Amundi Has $2.35 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

TAK|Takeda Pharmaceutical Co Ltd|Price:17.450|Chg%:+0.430

Earnings call transcript: Supernus and Indivior post Q2 2026 beat on merger news

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a Q2 2026 earnings beat and their planned all-stock merger. The combined entity will focus on central nervous system drugs, aiming for $2.2 billion in annual revenue and $125 million in annual cost savings. The merger, expected to …

Cronos Group (TSX:CRON) Is Up 6.4% After Swinging Back To Profit And Beating Q2 Expectations

Cronos Group (TSX:CRON) reported a strong second quarter in 2026, swinging back to a net profit of US$32.09 million and beating revenue and earnings expectations. The company achieved net income of US$45.84 million for the first half of 2026, with basic earnings per share …

Dr. Reddy's Laboratories slides Friday, still outperforms market

Dr. Reddy's Laboratories (500124) shares experienced a slight decline of 0.26% on Friday, closing at 1,172.00 Indian rupees, amidst a general downturn in the stock market where the BSE SENSEX Index (1) fell by 0.58%. Despite the dip, the company's performance still outpaced the …

Amphastar Pharmaceuticals Q2 Earnings Call Highlights

Amphastar Pharmaceuticals reported a 5% year-over-year revenue increase in Q2 2026, reaching $183.9 million, driven by new product launches like ipratropium bromide inhalation. Despite a slight dip in net income, diluted EPS rose, and the company is addressing an FDA warning letter at its …

Ishay Davidi Decides To Exercise Options At Kamada Worth $0

Ishay Davidi, a Director at Kamada (NASDAQ: KMDA), recently exercised stock options for 0 shares, valued at $0, as disclosed in an SEC filing on August 6, 2026. This transaction occurred while Kamada's shares were down by 0.14% at $7.17. The article also provides …

Breaking Update: Assaf Itshayek Engages In Options Exercise At Kamada Realizing $0

Assaf Itshayek, a Director at Kamada (NASDAQ: KMDA), exercised stock options for 0 shares, valued at $0, according to a recent SEC filing on August 6. This transaction occurred while Kamada shares were trading down 0.14% at $7.17. The article also provides a brief …

Insider Decision Making Waves At Kamada: David Tsur Exercises Options, Realizing $0

Kamada board member David Tsur exercised stock options for 0 shares, valued at $0, according to a recent SEC filing. The article highlights Kamada's strong financial performance, including a 2.78% revenue growth rate and a low debt-to-equity ratio of 0.04. It also emphasizes the …

As Competition Crowds Zoetis, We Lower Our Fair Value Estimate

Morningstar has lowered its fair value estimate for Zoetis (ZTS) due to increased competition in the animal health industry. Despite this, Zoetis is still considered the leader in the global animal health industry, known for its innovation across a wide range of products and …

Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?

Organogenesis (NASDAQ:ORGO) Issues Quarterly Earnings Results

Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc.

Harrow has entered into a definitive agreement to acquire Tyrvaya (varenicline solution), a dry eye nasal spray treatment, from Viatris Inc. This acquisition aims to expand Harrow's dry eye portfolio, complementing its Vevye franchise by offering a differentiated treatment option with a distinct mechanism …

HC Wainwright Predicts Indivior's Q3 Earnings (NASDAQ:INDV)

HC Wainwright has increased its Q3 2026 EPS estimates for Indivior (NASDAQ:INDV) to $0.93 from $0.78, with forecasts rising through FY2030. Despite a recent price target cut by Barclays, analyst sentiment remains a "Moderate Buy" with an average target of $45.17. Indivior's shares opened …

Collegium Pharmaceutical Releases Q2 2026 Financial Results

Collegium Pharmaceutical Inc. reported mixed Q2 2026 financial results, with adjusted earnings of $1.92 per share exceeding expectations, but revenue of $199.9M slightly missing estimates. The company's product, JORNAY PM, showed significant revenue growth of 41.0%, contributing to the positive outlook. Management issued full-year …

Kamada (KMDA) grants director 30,000 options at $7.5200 exercise price

Kamada Ltd. director Assaf Itshayek was granted 30,000 Employee Stock Options to acquire Ordinary Shares at an exercise price of $7.5200 per share. These options vest in four equal annual installments over four years and are exercisable for 10 years. The options are held …

IM Cannabis Corp. announced that it has received $0.225 million in funding

IM Cannabis Corp. announced that it has received $0.225 million in funding, as reported on August 6, 2026. The company also raised $250,000 through convertible note financing on August 7, 2026, and expects to receive another $0.225 million in funding. IM Cannabis Corp. is …

Earnings call transcript: SIGA posts $0.17 EPS in Q2 2026 as stock edges up

Phibro Animal Health (PAHC) CFO sells 840 shares to cover taxes

Phibro Animal Health's CFO, David Glenn, disposed of 840 shares of Class A Common Stock on August 4, 2026, at an average price of $36.599 per share. This transaction was a broker-assisted cashless exercise performed to satisfy tax withholding obligations related to the vesting …

Phibro Animal Health (NASDAQ: PAHC) COO sells 635 shares for tax withholding

Phibro Animal Health's Chief Operating Officer, Larry Lee Miller, sold 635 shares of Class A Common Stock on August 4, 2026, at a price of $36.599 per share. This transaction was a broker-assisted cashless exercise to cover tax withholding obligations associated with the vesting …

Phibro Animal Health (NASDAQ: PAHC) GC sells 472 shares for taxes

Phibro Animal Health's General Counsel, Judith Weinstein, sold 472 shares of Class A Common Stock on August 4, 2026, at $36.599 per share. This transaction was a broker-assisted cashless exercise to cover tax withholding obligations upon the vesting of restricted stock units. Following this …

A Quick Look at Today's Ratings for BioAge Labs(BIOA.US), With a Forecast Between $21 to $73

This article provides a brief overview of recent analyst ratings for BioAge Labs (BIOA.US), highlighting a wide forecast range for its stock price between $21 and $73. It indicates that these ratings come from investment analysts who are evaluating the company's future performance.

Elanco Animal Health Inc (ELAN) Shares Fall 7.7% -- What GF Score of 66 Tells Investors

Elanco Animal Health Inc (ELAN) shares recently fell 7.7% to $24.20, making it 8.5% down for the week. The stock is currently deemed significantly overvalued with a GF Value™ of $15.62, despite having an above-average GF Score™ of 66/100. While insider activity shows purchases, …

Amphastar P earnings beat by $0.28, revenue topped estimates

Earnings call transcript: Amphastar rises after q2 2026 revenue beat

SIGA Q2 2026 Earnings: Lower TPOXX Sales Compress Revenue and Margins

SIGA Technologies reported a significant decline in Q2 2026 revenue and EPS due to lower TPOXX product sales and an unfavorable product mix, which compressed margins. The company delivered TPOXX to both U.S. and international customers, but the completion of a key U.S. procurement …

Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary

Xeris Biopharma Holdings, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is provided by Refinitiv and is available to TradingView users with unlimited access to news articles.

Xeris Pharmaceuticals’ Earnings Call Highlights Growth Momentum

Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower

Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ...

Viatris Inc (VTRS) reported strong Q2 2026 results with $3.8 billion in revenues, a 3.5% operational growth year-over-year, and raised its full-year guidance. Key drivers included robust performance in Greater China and advancements in its R&D pipeline. The company also highlighted challenges such as …

Enterprise value to EBIT forward of Talphera, Inc. – DUS:R5XA

This page from TradingView provides financial data for Talphera, Inc. (R5XA) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBIT forward metric. The content emphasizes the financial overview of the company, indicating that no trades were made and the market …

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

Organogenesis (Nasdaq: ORGO) sets up $75M at-the-market stock sale

Organogenesis Holdings Inc. has established an at-the-market sales agreement with BTIG, LLC and Citizens JMP Securities, LLC to offer and sell up to $75 million of its Class A common stock. Sales will occur from time to time through the agents on the Nasdaq …

BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside

BioAge Labs, Inc. (BIOA) has seen its average 12-month price target cut to $35.62 from $39.88, according to 8 analysts, yet this still implies a significant 224% potential upside based on its closing price. Despite the target reduction, the consensus rating from 9 analysts …

Biofrontera Inc (BFRI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Biofrontera Inc (BFRI), detailing its current earnings forecast score, average price target from analysts, and expected revenue and EPS for upcoming quarters. Two analysts rate BFRI as a "Buy" with a price target of $6.00, suggesting a …